[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidade Federal Fluminense\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":243},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,73,98,125,146,167,187,209,223],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100586573","royal-jelly-as-a-strategy-to-modulate-inflammation-and-oxidative-stress-in-patients-with-systemic-arterial-hypertension-100586573",false,"NCT06917131","Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension","Inclusion Criteria:\n\n* Diagnosis of stage 1 hypertension\n* Regular treatment for more than 6 months\n* No changes in medication doses during the last 3 months\n\nExclusion Criteria:\n\n* Autoimmune diseases\n* Infectious diseases\n* Diabetes\n* Chronic kidney disease\n* Liver disease\n* Cancer\n* AIDS\n* Pregnant women\n* Use of catabolic drugs or antibiotics\n* Use of antioxidant vitamin supplements, prebiotics, probiotics, or synbiotics\n* Habitual intake of royal jelly\n* Allergy to bee stings\n* Acute myocardial infarction (AMI)\n* Stroke (CVA)","ALL","18 Years","75 Years",{"count":19,"type":20},34,"ESTIMATED","INTERVENTIONAL",[23],"NA","The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.",[26,27,28],"Hypertension","Cardiovascular Diseases (CVD)","Inflammation",[30,31,26,32],"royal jelly","inflammation","cardiovascular diseases","RECRUITING","2026-05-14",{"date":36,"type":37},"2026-05-19","ACTUAL",{"date":39,"type":37},"2024-09-18",{"date":41,"type":20},"2026-12-10",{"name":43,"class":44},"Universidade Federal Fluminense","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100549776","effects-of-royal-jelly-supplementation-in-chronic-kidney-disease-100549776","NCT06438445","Effects of Royal Jelly Supplementation in Chronic Kidney Disease","Effects of Royal Jelly Supplementation on Inflammation and Cellular Senescence in Chronic Kidney Disease Patients Under Hemodialysis","Inclusion Criteria:\n\n* patients with CKD undergoing hemodialysis for more than 6 months\n* patients with arteriovenous fistula (AVF) as vascular access.\n\nExclusion Criteria:\n\n* pregnant,\n* lactating,\n* smoker\n* patients using antibiotics and antioxidant supplements in the last three months\n* patients with autoimmune and infectious diseases,\n* patients with cancer, liver disease, and AIDS","70 Years",{"count":55,"type":20},30,[23],"The objective of this study is to evaluate the effects of royal jelly on inflammation and cellular senescence in patients with chronic kidney disease (CKD) on hemodialysis (HD).",[59,60,61],"Kidney Failure, Chronic","Oxidative Stress","Hemodialysis",[63,64,65,60],"Cellular Senescence","Renal Dialysis","Renal Insufficiency, Chronic",{"date":67,"type":37},"2026-05-18",{"date":69,"type":37},"2024-07-30",{"date":71,"type":20},"2027-04-05",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100546407","effects-of-jaboticaba-plinia-cauliflora-supplementation-in-chronic-kidney-disease-patients-100546407","NCT06394531","Effects of Jaboticaba (Plinia Cauliflora) Supplementation in Chronic Kidney Disease Patients","Jaboticaba (Plinia Cauliflora) as a Strategy to Modulate Inflammation, Oxidative Stress, and Gut Dysbiosis in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Aged 18 to 75 years\n* Clinical diagnosis of Chronic Kidney Disease\n* Conservative treatment group: CKD stages 3 and 5 receiving nutritional treatment for at least 6 months\n* Hemodialysis group: Hemodialysis patients for more than 6 months\n\nExclusion Criteria:\n\n* Patients pregnant\n* Smokers\n* Using antibiotics in the last 3 months\n* Autoimmune diseases\n* Clinical diagnosis of infectious diseases\n* Clinical diagnosis of Cancer\n* Clinical diagnosis of AIDS",{"count":55,"type":20},[23],"The increase prevalence of chronic kidney disease (CKD) over the years represent a significant public health problem. The role of inflammation and oxidative stress in the pathophysiology of CKD, as well as progression and comorbidities, is already well consolidated. The gut microbiota composition imbalance may also be a risk factor contributing to the increased conditions mentioned above, and to uremic toxins release and endotoxemia. The literature has indicated the use of bioactive compounds as a nonpharmacological treatment strategies for the management of non-communicable diseases (NCDs), such as CKD and its complications. In this context, jaboticaba (Plinia Cauliflora) emerges as a potential therapeutic approach as it is a source of phenolic compounds, such as anthocyanins, flavonols, ellagitannins, and phenolic acids. Such phenolic compounds may have beneficial effects in patients with CKD, such as anti-inflammatory, antioxidant, modulation of the intestinal microbiota, hypotensive and hypoglycemic effects. These combined effects can help manage risk factors and CKD itself, and associated complications. Therefore, this research project aims to add scientific knowledge, providing a non-pharmacological therapeutic approach to be implemented in clinical practice and in the care of patients with CKD, with the aim of modulating inflammation, oxidative stress, microbiota composition, and improving the quality of life of these patients. Therefore, this study aims to evaluate the effects of jaboticaba (Plinia Cauliflora) supplementation on complications associated with CKD.",[84],"Chronic Kidney Diseases",[86,87,31,88,89],"chronic kidney diseases","jaboticaba","oxidative stress","microbitoa","NOT_YET_RECRUITING",{"date":92,"type":37},"2026-05-15",{"date":94,"type":20},"2026-07-01",{"date":96,"type":20},"2028-07-01",{"name":43,"class":44},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100538236","green-propolis-extract-and-royal-jelly-in-hypertensive-patients-andor-with-chronic-kidney-disease-100538236","NCT06288204","Green Propolis Extract and Royal Jelly in Hypertensive Patients and\u002For With Chronic Kidney Disease","Association of Green Propolis Extract and Royal Jelly to Modulate Inflammation and Oxidative Stress in Hypertensive Patients and\u002For With Chronic Kidney Disease","Inclusion Criteria:\n\n* patients in stages 3 and 5 of CKD (GFR from 15 to 59 mL\u002Fmin),\n* patients receiving ambulatorial nutrition treatment at least 6 months\n* patients on regular Hemodialysis treatment for at least 6 months\n* patients using one to three antihypertensive drugs\n\nExclusion Criteria:\n\n* autoimmune and infectious diseases,\n* diabetes\n* cancer\n* AIDS\n* pregnant women\n* patients using catabolic drugs or antibiotics;\n* patients with catheter access to hemodialysis;\n* patients using antioxidant vitamin supplements, prebiotics, probiotics, symbiotic,\n* Patients on regular intake of propolis who are allergic to corn starch or report being allergic to bee stings.\n* patients with acute myocardial infarction (AMI) and\u002For cerebrovascular accident (CVA)",{"count":106,"type":20},153,[23],"This work aims to evaluate the effects of the association of green propolis extract with royal jelly on inflammation and oxidative stress in participants with chronic kidney diseases (CKD) and Systemic arterial hypertension (SAH), in a longitudinal, randomized, double-blind, placebo-controlled clinical trial that will be carried out for 2 months.",[84,26,110],"Cardiovascular Diseases",[112,113,114,31,88,115,30,116,117],"chronic kidney disease","hypertension","cardiovascular disease","green propolis","Nrf2","Nuclear factor kappa-B",{"date":92,"type":37},{"date":120,"type":37},"2024-10-01",{"date":122,"type":20},"2027-07-31",{"name":43,"class":44},2,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":145,"locationsCount":45},"100538124","beetroot-extract-supplementation-associated-with-an-exercise-protocol-for-chronic-kidney-disease-patients-100538124","NCT06286748","Beetroot Extract Supplementation Associated With an Exercise Protocol for Chronic Kidney Disease Patients","Effects of Beetroot Extract Supplementation Associated With an Exercise Protocol on Oxidative Stress, Inflammation, and Functional Capacity in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Patients with CKD undergoing conservative treatment (stages G3a-G4);\n* Aged between 18 and 65 years old;\n* Patients undergoing nutritional monitoring for more than 6 months.\n\nExclusion Criteria:\n\n* Patients using catabolic drugs;\n* Smokers\n* Pregnant women;\n* Using antibiotics and of proton pump inhibitors in the last 3 months;\n* Antioxidant supplements and habitual intake of beetroot or nitrate supplement;\n* Those who are clinically unstable (unstable angina, atrial fibrillation, significant cardiac arrhythmia and acute illness in the last month; and glycemic lability);\n* Unable to exercise (amputation without prosthesis); musculoskeletal pain at rest or with minimal physical activity, inability to sit or walk without assistance, use of a walking device, dyspnea at rest or with light exertion;\n* Those with autoimmune diseases and infectious diseases, cancer, liver disease and AIDS.\n* Patients with parathormone (PTH) levels above 500pg\u002FmL;\n* Those who are allergic or intolerant to the components of the juice.\n* Patients with any impediment to completing the proposed exercise protocol, such as due to travel or difficulty accessing the location where the research will be carried out.","65 Years",{"count":134,"type":20},25,[23],"Chronic kidney disease (CKD) patients often present systemic inflammation and oxidative stress, resulting in metabolic disorders and high rates of disease-associated cardiovascular death. The literature has indicated that dietary control, the use of bioactive compounds, and the practice of regular physical exercise are essential for the prevention and management of CKD and its complications. In this context, beetroot (Beta vulgaris rubra) deserves attention as it is a source of several bioactive compounds, such as nitrate, betaine, and betalain, with beneficial effects for CKD patients, including anti-inflammatory, antioxidant effects, reduction of blood pressure, and vasodilatory action. The antioxidant and anti-inflammatory properties, in addition to their vasodilatory and antihypertensive capacity, can make supplementation of beetroot an excellent nutritional strategy to help in the treatment of CKD patients. So, this research project will bring contributions to the scientific world, providing strategies for application in clinical practice and the care of patients with CKD, on the use of beetroot associated with an exercise protocol as a non-pharmacological strategy in modulating inflammation, oxidative stress, and improved functional capacity. Furthermore, when supplemented hours before physical training, has been identified as an important factor in improving performance in these activities. Therefore, this study aims to evaluate the effects of supplementation (acute and chronic) of beetroot extract associated with an exercise protocol on complications associated with CKD.",[84],[112,139,140,31,88],"beetroot","exercise",{"date":92,"type":37},{"date":143,"type":37},"2024-04-10",{"date":41,"type":20},{"name":43,"class":44},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":164,"leadSponsor":166,"locationsCount":45},"100640154","ginger-in-the-modulation-of-inflammatory-cytokines-and-oxidative-stress-in-patients-with-coronary-artery-disease-100640154","NCT07596979","Ginger in the Modulation of Inflammatory Cytokines and Oxidative Stress in Patients With Coronary Artery Disease","Inclusion Criteria:\n\n* Both sexes\n* Over 18 years of age;\n* Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);\n* Participants who are asymptomatic or have angina limited to functional class III will be considered;\n* Patients who have already undergone coronary revascularization and angioplasty may participate;\n* the last acute coronary event must have occurred more than one year ago.\n\nExclusion Criteria:\n\n* Unstable Coronary Artery Disease;\n* Pre-operative coronary artery bypass grafting or awaiting elective angioplasty;\n* Unstable angina;\n* NYHA functional class III or higher;\n* Advanced chronic kidney disease (creatinine clearance \\\u003C 30 ml\u002Fmin\u002F1.73 m²);\n* Individuals with autoimmune diseases.",{"count":153,"type":20},50,[23],"The study aims to evaluate the effect of ginger supplementation on inflammatory cytokines and markers of oxidative stress in patients with Coronary Artery Disease (CAD). A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.",[157,60,28],"Coronary Artery Disease (CAD)",[159,160,31,88],"ginger","coronary artery disease","2026-05-12",{"date":36,"type":37},{"date":67,"type":20},{"date":165,"type":20},"2028-12",{"name":43,"class":44},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":45},"100639653","effects-of-propolis-and-royal-jelly-supplementation-on-inflammatory-and-oxidative-stress-markers-in-patients-with-systemic-arterial-hypertension-100639653","NCT07596966","EFFECTS OF PROPOLIS AND ROYAL JELLY SUPPLEMENTATION ON INFLAMMATORY AND OXIDATIVE STRESS MARKERS IN PATIENTS WITH SYSTEMIC ARTERIAL HYPERTENSION","Inclusion Criteria:\n\n* Diagnosis of stage 1 and 2 hypertension\n* Regular treatment for more than 6 months\n* There have been no changes in medication doses over the last three months.\n\nExclusion Criteria:\n\n* Autoimmune and infectious diseases, diabetes\n* Chronic kidney disease, liver disease, cancer and AIDS\n* Pregnant women\n* Use of catabolic drugs or antibiotics\n* Use of antioxidant vitamin supplements, prebiotics, probiotics, symbiotic\n* Habitual intake of royal jelly and propolis",{"count":174,"type":20},48,[23],"The study aims to evaluate the effect of the royal jelly and propolis on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.",[178,28],"Systemic Arterial Hypertension",[31,30,180,113,88],"propolis",{"date":36,"type":37},{"date":183,"type":37},"2025-10-15",{"date":185,"type":20},"2027-12-10",{"name":43,"class":44},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":132,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":45},"100637286","red-propolis-supplementation-as-a-strategy-in-chronic-kidney-disease-100637286","NCT07597005","Red Propolis Supplementation as a Strategy in Chronic Kidney Disease","Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* patients with CKD stages 3-5 under conservative management\n\nExclusion Criteria:\n\n* pregnant,\n* lactating,\n* smoker\n* patients using antibiotics and antioxidant supplements in the last three months\n* patients with autoimmune and infectious diseases,\n* patients with cancer, liver disease, and AIDS",{"count":195,"type":20},40,[23],"The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.",[199,60,200,28],"Kidney Disease","Chronic Kidney Disease",[88,202,31,112],"red propolis",{"date":36,"type":37},{"date":205,"type":37},"2025-09-30",{"date":207,"type":20},"2027-08-31",{"name":43,"class":44},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":215,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":221,"leadSponsor":222,"locationsCount":45},"100640646","effects-of-royal-jelly-and-propolis-on-metabolomic-signatures-inflammation-and-cardiovascular-risk-in-patients-with-coronary-artery-disease-100640646","NCT07596992","Effects of Royal Jelly and Propolis on Metabolomic Signatures, Inflammation, and Cardiovascular Risk in Patients With Coronary Artery Disease.",{"count":153,"type":20},[23],"The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.",[157,60,28],[30,180,160,88,31],{"date":36,"type":37},{"date":67,"type":20},{"date":165,"type":20},{"name":43,"class":44},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":45},"100530171","effects-of-nattokinase-on-inflammation-and-cardiovascular-risk-markers-in-patients-with-dyslipidemia-100530171","NCT06183307","Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia","Inclusion Criteria:\n\n* Both sexes;\n* Over 18 years of age;\n* Isolated increase in LDL-c (LDL-c ≥ 160 mg\u002FdL);\n* Isolated increase in triglycerides (TG ≥ 150 mg\u002FdL or ≥ 175 mg\u002FdL, without fasting);\n* increased LDL-c (LDL-c ≥ 160 mg\u002FdL)\n* TG (TG ≥ 150 mg\u002FdL or ≥ 175 mg\u002FdL, without fasting);\n* Reduction in HDL-c (men \\\u003C 40 mg\u002FdL and women \\\u003C 50 mg\u002FdL) alone or in association with an increase in LDL-c or TG. If TG ≥ 400 mg\u002FdL.\n* Individuals who are already using lipid-lowering therapy (statins or non-statins) will also be included.\n\nExclusion Criteria:\n\n* Participants with autoimmune and infectious diseases, diabetes, cancer and AIDS;\n* Pregnant women;\n* Participants using catabolic drugs or antibiotics\n* Participants on anticoagulant medication\n* Participants using antioxidant vitamin supplements, prebiotic, probiotic or synbiotic and who are allergic to corn or soy starch.",{"count":174,"type":20},[23],"The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants with dyslipidemia for two months.",[110,233,28],"Dyslipidemias",[235,110,28,236],"nattokinase","fibrinogen",{"date":34,"type":37},{"date":239,"type":37},"2024-08-03",{"date":241,"type":20},"2026-12-20",{"name":43,"class":44},""]